Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.39 and has seen 0.44 million shares traded in the recent trading session. The company, currently valued at $410.90M, closed the recent trade at $2.01 per share which meant it lost -$0.02 on the day or -1.23% during that session. The TSHA stock price is -114.93% off its 52-week high price of $4.32 and 36.82% above the 52-week low of $1.27. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.96 million shares traded. The 3-month trading volume is 2.08 million shares.
The consensus among analysts is that Taysha Gene Therapies Inc (TSHA) is Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting -1.23% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TSHA stock price touched $2.01 or saw a rise of 12.23%. Year-to-date, Taysha Gene Therapies Inc shares have moved 13.28%, while the 5-day performance has seen it change -8.03%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed -8.86%. Short interest in the company has seen 21.66 million shares shorted with days to cover at 18.61.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 76.35% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $44.0. In that case, then, we find that the latest price level in today’s session is -2089.05% off the targeted high while a plunge would see the stock gain -148.76% from the levels at last check today.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Figures show that Taysha Gene Therapies Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -34.48% over the past 6 months, with this year growth rate of 63.54%, compared to 21.20% for the industry. Revenue growth from the last financial year stood is estimated to be -45.80%.
11 analysts offering their estimates for the company have set an average revenue estimate of 1.65M for the current quarter. 11 have an estimated revenue figure of 2.33M for the next ending quarter. Year-ago sales stood 4.75M and 3.6M respectively for this quarter and the next, and analysts expect sales will shrink by -65.20% for the current quarter and -45.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -137.69% over the past 5 years.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report on 2024-Nov-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders own 17.54% of the company shares, while shares held by institutions stand at 77.68% with a share float percentage of 94.20%. Investors are also buoyed by the number of investors in a company, with Taysha Gene Therapies Inc having a total of 146.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 21.21 million shares worth more than $47.51 million. As of 2024-06-30, FMR LLC held 9.1722% of shares outstanding.
The other major institutional holder is RTW INVESTMENTS, LP, with the holding of over 18.8 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.11 million and represent 8.1299% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. As of Jul 31, 2024, the former fund manager holds about 3.60% shares in the company for having 7.38 shares of worth $14.8 million while later fund manager owns 4.46 shares of worth $8.93 million as of Jun 30, 2024, which makes it owner of about 2.17% of company’s outstanding stock.
